Who manufactures Ninlaro (Ixazomib)?

Ixazomib Capsule bulk supplier for pharma manufacturers

Ixazomib Capsule 2.3mg, 3mg, 4mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 2.3mg, 3mg, 4mg

Reference Brands: Ninlaro (US/EU)

Ixazomib is used in adults to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone. This combination is usually given after treatment with at least one other cancer medicine has failed.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ixazomib Capsule? List it or send an offer →

Product Description:

Ixazomib inhibits the proteasome, the cell's protein disposal machinery. Myeloma cells produce immunoglobulin in enormous quantities and depend on that machinery more heavily than any normal cell, so blocking it causes misfolded protein to accumulate to lethal levels. What separates ixazomib from earlier proteasome inhibitors is that it is absorbed orally and binds reversibly with a short dissociation time, allowing weekly rather than twice-weekly dosing.

It is used for multiple myeloma in combination with lenalidomide and dexamethasone, in patients who have received at least one prior therapy, taken once weekly for three weeks of a four-week cycle. Because all three drugs in the regimen are oral, the whole treatment can be delivered without infusion visits, which changes what is feasible for patients distant from a centre. Thrombocytopenia follows a predictable cyclical pattern; diarrhoea, constipation, nausea, rash and peripheral neuropathy occur, the neuropathy notably less than with injectable agents.

Sourcing notes. Originator product, on patent, supplied in three capsule strengths for dose reduction. Capsules must stay in the original blister until use — they are moisture-sensitive — and must be swallowed whole on an empty stomach. Room temperature storage. Quoted alongside lenalidomide.

How Ixazomib Capsule is supplied today, and licensing ahead of patent expiry

Ixazomib Capsule is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ixazomib Capsule, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ixazomib Capsule supply →

Back to Listing

Frequently Asked Questions

Ninlaro (Ixazomib) is developed and sold by Takeda. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.